Heart failure drug dapagliflozin under Real-World microscope in greece

NCT ID NCT05635331

Completed Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study in Greece observed 257 adults with heart failure who were prescribed dapagliflozin as part of their routine care. Researchers tracked how long patients stayed on the drug, any changes in their other heart medications, and how their quality of life changed over time. The goal was to understand how this approved medication works in everyday practice, outside of a controlled clinical trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dapagliflozin
What this could lead to: If successful, this study could provide real-world insights into how dapagliflozin is used and tolerated in everyday heart failure care, potentially improving treatment guidelines.
What could go wrong: This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by patient selection and other factors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE

Contacts and locations

Locations

Research Site

Alexandroupoli, 68100, Greece
Research Site

Athens, 11526, Greece
Research Site

Athens, 11527, Greece
Research Site

Athens, 11528, Greece
Research Site

Athens, 12462, Greece
Research Site

Athens, 14233, Greece
Research Site

Athens, 17674, Greece
Research Site

Chania, 73300, Greece
Research Site

Heraklion, 71409, Greece
Research Site

Ioannina, 45445, Greece
Research Site

Ioannina, 45500, Greece
Research Site

Pátrai, 26504, Greece
Research Site

Thessaloniki, 54636, Greece
Research Site

Thessaloniki, 54642, Greece
Research Site

Thessaloniki, 56429, Greece
Research Site

Thessaloniki, 57010, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.